Antisense nucleic acids

  • US 10,647,741 B2
  • Filed: 06/24/2019
  • Issued: 05/12/2020
  • Est. Priority Date: 09/01/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method comprising administering to a patient with DMD an antisense phosphorodiamidate morpholino oligomer (PMO) consisting of a 25-mer oligomer that is 100% complementary to the 36th to the 60th nucleotides from the 5′

  • end of the 53rd exon in a human dystrophin pre-mRNA, wherein the 53rd exon in said human dystrophin pre-mRNA consists of a nucleotide sequence corresponding to SEQ ID NO;

    1, wherein said PMO hybridizes to said human dystrophin pre-mRNA with Watson-Crick base pairing, and wherein skipping of the 53rd exon is induced in said patient.

View all claims

    Thank you for your feedback